About the Class Action / Mass Tort
The risks associated with Tenofovir were well-understood by the Defendants at the time they began developing and testing TDF-based drugs.
As a result of taking the TDF-based drugs, individuals suffered harm and injuries including, but not limited to, decreased kidney function, renal failure, end-stage renal disease, renal impairment, chronic kidney disease, tubular dysfunction, chronic liver disease, Fanconi syndrome, reduced bone density, bone breaks/fractures, bone malformation, and tooth loss.
This claim is being brought on behalf of all individuals who, during the period 2004 to the present were prescribed and ingested TDF-based drugs in Canada and experienced any of the harm and injuries described above.
Updates (Related to the Class Action / Mass Tort)
– April 2022: We write to provide you with a further update to our December update. As mentioned in our last update, we have issued our Statement of Claim. We are currently in the process of conducting internal meetings to discuss next steps. Once these talks have been completed, we will provide a further update.
– December 2021: We write to provide you with a further update to our August update. As mentioned in our last update, we have issued our Statement of Claim. We are awaiting a response from defence counsel and will be moving towards booking our first court appearance.
– August 2021: We write to provide you with a further update to our June 9th update. As mentioned in our last update, we are currently drafting a Statement of Claim and anticipate that claim will be issued in the near future. Once the claim is issued we will be proceeding with the next steps, which include booking a first court appearance.
